Live Topical Biotherapeutics for the Treatment of Inflammatory Skin Disorders

An evolutionary approach to restoring health

AOBiome Therapeutics is a late stage therapeutics company addressing a broad range of inflammatory skin conditions by harnessing a single strain of class defining Ammonia Oxidizing Bacteria (AOB), whose presence on the skin has been eliminated through modern living.


Ammonia Oxidizing Bacteria may serve to restore proper immune response through the down regulation of IL-4, IL-5, IL-13 and IL-31. Such markers are associated with inappropriate inflammatory response in several diseases including the pruritus (itch) pathway.

AOBiome currently has multiple
Phase 2 clinical programs

AOBiome currently has Phase 2 clinical programs in acne, eczema and rosacea.


Learn More

Committed to transforming & improving human health

We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.


In the News
AOBiome announces the publication of positive Phase 2b results in The Lancet’s eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus
AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244
Todd Krueger, the President & CEO of AOBiome Therapeutics, Inc., featured in Business Talk’s latest edition, “Top 10 Global Business Leaders Making a Difference in 2022”
AOBiome Listed by The Silicon Review as one of the 50 Innovative companies to watch in 2022